Literature DB >> 35104370

Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review.

Elizaveta Belyaeva1, Ayelet Rubenstein2, Sheila K Pierson2, Delaney Dalldorf3, Dale Frank4, Megan S Lim4, David C Fajgenbaum2.   

Abstract

Idiopathic multicentric Castleman disease (iMCD) is a polyclonal lymphoproliferative disorder characterized by constitutional symptoms, generalized lymphadenopathy, cytopenias, and multi-organ dysfunction due to excessive cytokines, notably Interleukin-6. Idiopathic multicentric Castleman disease is often sub-classified into iMCD-TAFRO, which is associated with thrombocytopenia (T), anasarca (A), fever/elevated C-reactive protein (F), renal dysfunction (R), and organomegaly (O), and iMCD not otherwise specified (iMCD-NOS), which is typically associated with thrombocytosis and hypergammaglobulinemia. The diagnosis of iMCD is challenging as consensus clinico-pathological diagnostic criteria were only recently established and include several non-specific lymph node histopathological features. Identification of further clinico-pathological features commonly found in iMCD could contribute to more accurate and timely diagnoses. We set out to characterize bone marrow (BM) histopathological features in iMCD, assess differences between iMCD-TAFRO and iMCD-NOS, and determine if these findings are specific to iMCD. Examination of BM specimens from 24 iMCD patients revealed a high proportion with hypercellularity, megakaryocytic atypia, reticulin fibrosis, and plasmacytosis across patients with both iMCD-NOS and iMCD-TAFRO with significantly more megakaryocytic hyperplasia (p = 0.001) in the iMCD-TAFRO cases. These findings were also consistent with BM findings from 185 published cases of iMCD-NOS and iMCD-TAFRO. However, these findings are relatively nonspecific as they can be seen in various other infectious, malignant, and autoimmune diseases.
© 2022 John Wiley & Sons Ltd.

Entities:  

Keywords:  bone marrow; castleman disease; iMCD; megakaryocytic hyperplasia; plasmacytosis; reticulin fibrosis

Mesh:

Year:  2022        PMID: 35104370      PMCID: PMC9547646          DOI: 10.1002/hon.2969

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   4.850


  39 in total

Review 1.  Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres.

Authors:  David J Kuter; Barbara Bain; Ghulam Mufti; Adam Bagg; Robert P Hasserjian
Journal:  Br J Haematol       Date:  2007-11       Impact factor: 6.998

2.  Megakaryocytic alterations in thrombocytopenia: a bone marrow aspiration study.

Authors:  Manas Muhury; Alka M Mathai; Sharada Rai; Ramadas Naik; Muktha R Pai; Ruchi Sinha
Journal:  Indian J Pathol Microbiol       Date:  2009 Oct-Dec       Impact factor: 0.740

3.  Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease.

Authors:  K Yoshizaki; T Matsuda; N Nishimoto; T Kuritani; L Taeho; K Aozasa; T Nakahata; H Kawai; H Tagoh; T Komori
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

Review 4.  The bone marrow trephine biopsy: a review of normal histology.

Authors:  D C Brown; K C Gatter
Journal:  Histopathology       Date:  1993-05       Impact factor: 5.087

5.  Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.

Authors:  J T Beck; S M Hsu; J Wijdenes; R Bataille; B Klein; D Vesole; K Hayden; S Jagannath; B Barlogie
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

6.  The role of interleukin 6 and interleukin 1 in megakaryocyte development.

Authors:  M K Warren; L B Conroy; J S Rose
Journal:  Exp Hematol       Date:  1989-12       Impact factor: 3.084

Review 7.  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum
Journal:  Blood       Date:  2018-11-29       Impact factor: 22.113

8.  Effects of human interleukin-6 on megakaryocyte development and thrombocytopoiesis in primates.

Authors:  C P Stahl; D Zucker-Franklin; B L Evatt; E F Winton
Journal:  Blood       Date:  1991-09-15       Impact factor: 22.113

9.  The clinical spectrum of Castleman's disease.

Authors:  Angela Dispenzieri; James O Armitage; Matt J Loe; Susan M Geyer; Jake Allred; John K Camoriano; David M Menke; Dennis D Weisenburger; Kay Ristow; Ahmet Dogan; Thomas M Habermann
Journal:  Am J Hematol       Date:  2012-07-13       Impact factor: 10.047

10.  Regulation of megakaryocyte development by interleukin-6.

Authors:  J Lotem; Y Shabo; L Sachs
Journal:  Blood       Date:  1989-10       Impact factor: 22.113

View more
  2 in total

1.  Thrombocytopenia, anasarca, and severe inflammation.

Authors:  Amanallah Montazeripouragha; Christine M Campbell; James Russell; Nadia Medvedev; Daniel R Owen; Alison Harris; Fergal Donnellan; Iain McCormick; David C Fajgenbaum; Luke Y C Chen
Journal:  Am J Hematol       Date:  2022-07-19       Impact factor: 13.265

2.  How we manage idiopathic multicentric Castleman disease.

Authors:  Joshua D Brandstadter; David C Fajgenbaum
Journal:  Clin Adv Hematol Oncol       Date:  2022-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.